Year |
Citation |
Score |
2023 |
DePeaux K, Rivadeneira DB, Lontos K, Dean VG, Gunn WG, Watson MJ, Yao T, Wilfahrt D, Hinck C, Wieteska L, Thorne SH, Hinck AP, Delgoffe GM. An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment. The Journal of Experimental Medicine. 220. PMID 37552475 DOI: 10.1084/jem.20230053 |
0.332 |
|
2019 |
Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, Sampath P, Lafyatis R, Ferris RL, Sarkar SN, Thorne SH, Delgoffe GM. Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity. PMID 31471106 DOI: 10.1016/J.Immuni.2019.07.003 |
0.366 |
|
2018 |
Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, Watkins SC, Delgoffe GM. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. The Journal of Experimental Medicine. PMID 29511066 DOI: 10.1084/Jem.20171068 |
0.347 |
|
2018 |
Rivadeneira DB, Delgoffe GM. Antitumor T cell reconditioning: improving metabolic fitness for optimal cancer immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29386217 DOI: 10.1158/1078-0432.Ccr-17-0894 |
0.347 |
|
2017 |
Caino MC, Seo JH, Wang Y, Rivadeneira DB, Gabrilovich DI, Kim ET, Weeraratna AT, Languino LR, Altieri DC. Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer. The Journal of Clinical Investigation. PMID 28891816 DOI: 10.1172/JCI93172 |
0.401 |
|
2016 |
Seo JH, Rivadeneira DB, Caino MC, Chae YC, Speicher DW, Tang HY, Vaira V, Bosari S, Palleschi A, Rampini P, Kossenkov AV, Languino LR, Altieri DC. The Mitochondrial Unfoldase-Peptidase Complex ClpXP Controls Bioenergetics Stress and Metastasis. Plos Biology. 14: e1002507. PMID 27389535 DOI: 10.1371/journal.pbio.1002507 |
0.346 |
|
2015 |
Rivadeneira DB, Caino MC, Seo JH, Angelin A, Wallace DC, Languino LR, Altieri DC. Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion. Science Signaling. 8: ra80. PMID 26268608 DOI: 10.1126/scisignal.aab1624 |
0.443 |
|
2015 |
Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A, Rampini P, Kossenkov AV, Aird KM, Zhang R, Webster MR, Weeraratna AT, Bosari S, Languino LR, Altieri DC. PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proceedings of the National Academy of Sciences of the United States of America. PMID 26124089 DOI: 10.1073/Pnas.1500722112 |
0.408 |
|
2014 |
Faversani A, Vaira V, Moro GP, Tosi D, Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC, Bosari S. Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. Breast Cancer Research : Bcr. 16: R55. PMID 24886669 DOI: 10.1186/bcr3666 |
0.384 |
|
2014 |
Witkiewicz AK, Cox DW, Rivadeneira D, Ertel AE, Fortina P, Schwartz GF, Knudsen ES. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer. Oncogene. 33: 3980-91. PMID 24121271 DOI: 10.1038/Onc.2013.367 |
0.675 |
|
2012 |
McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, Farber JL, Force T, Koch WJ, Knudsen ES. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle (Georgetown, Tex.). 11: 2747-55. PMID 22751436 DOI: 10.4161/Cc.21127 |
0.65 |
|
2011 |
Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. The American Journal of Pathology. 179: 1171-8. PMID 21756866 DOI: 10.1016/J.Ajpath.2011.05.043 |
0.649 |
|
2011 |
McClendon AK, Dean JL, Ertel A, Fu Z, Rivadeneira DB, Reed CA, Bourgo RJ, Witkiewicz A, Addya S, Mayhew CN, Grimes HL, Fortina P, Knudsen ES. RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology. 141: 1439-50. PMID 21704587 DOI: 10.1053/J.Gastro.2011.06.046 |
0.581 |
|
2011 |
McClendon K, Dean JL, Rivadeneira D, Reed CA, Witkiewicz A, Gao E, Koch WJ, Force T, Knudsen ES. Abstract 591: Expanding the therapeutic window through pharmacological activation of the RB pathway in breast cancer treatment Cancer Research. 71: 591-591. DOI: 10.1158/1538-7445.Am2011-591 |
0.665 |
|
2011 |
Rivadeneira D, Mercier I, Lisanti MP, Witkiewicz A, Knudsen ES. Abstract 233: Crosstalk of Her2 signaling and cell cycle control in the response to targeted therapeutics in breast cancer Cancer Research. 71: 233-233. DOI: 10.1158/1538-7445.Am2011-233 |
0.703 |
|
2010 |
Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (Georgetown, Tex.). 9: 3256-76. PMID 20814239 DOI: 10.4161/Cc.9.16.12553 |
0.609 |
|
2010 |
Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Graña X, Knudsen ES. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 138: 1920-30. PMID 20100483 DOI: 10.1053/J.Gastro.2010.01.007 |
0.615 |
|
2010 |
Rivadeneira D, Ertel A, Witkiewicz A, Mercier I, Lisanti M, Knudsen E. Abstract P4-01-04: The Impact of the Retinoblastoma Tumor Suppressor Pathway in Her2 Positive Breast Cancer Pathogenesis and Therapeutic Response Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P4-01-04 |
0.689 |
|
Show low-probability matches. |